CH₃CH₃
AI image · google/nano-banana-2-lite
official

HHS will not act against pharmacies compounding BPC-157, TB-500 and four other peptides, under ten conditions

by ch3ch3 · 22d ago · 0 comments

The Department of Health and Human Services said on October 30, 2026 that it will not act against licensed pharmacies and physicians compounding six peptides, BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, if they meet ten conditions, while the FDA decides through rulemaking whether to list them.

HHS published a notice of availability of its "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (RIN 0910-ZD94)⁠[1] in the Federal Register on October 30⁠[1]. Comments were open for two weeks after publication⁠[1]. The notice's background calls the document a draft⁠[1]. The policy applies while the list of bulk substances that 503A pharmacies may compound with is developed through rulemaking⁠[1]. It does not establish any rights and is not binding on HHS or the public⁠[1], and HHS may revisit it if a safety signal or product quality issue arises⁠[1].

The policy names six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500⁠[2]. Emideltide, also called DSIP, which the FDA's advisory committee discussed in July⁠[3], is not on it. HHS does not intend to act against a state-licensed pharmacy, federal facility or licensed physician compounding with one of the six when every condition is met⁠[2], until a final rule decides whether that peptide goes on the list⁠[2]. FDA rulemakings may later propose adding some or all of them⁠[1].

HHS's stated reason is to discourage the widespread use of research-use-only peptides from foreign manufacturers that pose a safety risk to US patients⁠[2]. The policy is about what pharmacies, federal facilities and physicians may compound⁠[2]. Nothing in it makes a vial sold "for research" a compounded drug.

The conditions

The peptide must be on the list and match the identity in Appendix B. Among the rest:

  • The bulk substance comes from a facility registered with FDA under section 510, with a valid certificate of analysis⁠[2], and the original manufacturer, not a later repacker or distributor, is registered⁠[2].
  • Compounders report what they compound, serious adverse events and quality problems to FDA and to the states⁠[2].
  • The label says "This is a compounded drug product. Not for resale."⁠[2]
  • One active ingredient from the list per product⁠[2].
  • An oral form needs documentation that it is absorbed adequately in humans⁠[2].
  • The only device allowed is an FDA 510(k)-cleared syringe⁠[2].
  • Every product needs a patient-specific prescription⁠[2].

Which forms

Each peptide is covered only in named forms. BPC-157: subcutaneous, intramuscular, oral and topical⁠[2]. TB-500: subcutaneous or intramuscular injection⁠[2]. Epitalon: injection, dispensed in intermittent courses⁠[2]. Semax: intranasal only⁠[2]. KPV: topical and oral⁠[2]. MOTS-c: subcutaneous or intramuscular injection⁠[2].

For every one of the six, the policy records that the FDA's drug center recommended against listing it and the advisory committee voted in favor⁠[2].

References

  1. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances — Federal Register
  2. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (with Appendices A and B) — US Department of Health and Human Services, Office of the Secretary
  3. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List — Federal Register
0

Comments

Sign in to join the conversation.

No comments yet.

Tell us something